BiotechTube

Acetylsalicylic acid (Fast release Aspirin, BAY1019036) + Acetylsalicylic Acid (Aspirin, BAYE4465) + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Drugs, Investigational

Conditions

Drugs, Investigational

Trial Timeline

Apr 28, 2010 → Jul 7, 2010

NCT ID
NCT01117636

About Acetylsalicylic acid (Fast release Aspirin, BAY1019036) + Acetylsalicylic Acid (Aspirin, BAYE4465) + Placebo

Acetylsalicylic acid (Fast release Aspirin, BAY1019036) + Acetylsalicylic Acid (Aspirin, BAYE4465) + Placebo is a phase 3 stage product being developed by Bayer for Drugs, Investigational. The current trial status is completed. This product is registered under clinical trial identifier NCT01117636. Target conditions include Drugs, Investigational.

What happened to similar drugs?

0 of 2 similar drugs in Drugs, Investigational were approved

Approved (0) Terminated (0) Active (2)
🔄HR17031 injection + insulin glargineJiangsu Hengrui MedicinePhase 3
🔄Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036) + Acetylsalicyclic acid (Aspirin, BAYE4465) + PlaceboBayerPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01117636Phase 3Completed

Competing Products

6 competing products in Drugs, Investigational

See all competitors
ProductCompanyStageHype Score
HR17031 injection + insulin glargineJiangsu Hengrui MedicinePhase 3
40
SHR-1603Jiangsu Hengrui MedicinePhase 1
33
Famitinib + Ifosfamide + CamrelizumabJiangsu Hengrui MedicinePhase 1/2
24
bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF)Gilead SciencesPre-clinical
26
SintilimabInnovent BiologicsPhase 2
35
Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036) + Acetylsalicyclic acid (Aspirin, BAYE4465) + PlaceboBayerPhase 3
37